Repligen Corporation - Common Stock (RGEN)
174.37
-5.80 (-3.22%)
NASDAQ · Last Trade: Oct 27th, 1:34 PM EDT
News & Press Releases
Repligen (RGEN) Q3 2026 Earnings Call Transcriptfool.com
BioLife acquisition bolsters cell therapy as chromatography and proteins surge.
Via The Motley Fool · October 27, 2026
What Repligen (RGEN) Said on Its Q3 Earnings Callmarketbeat.com
Repligen (NASDAQ:RGEN) reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises offset weakness in Filtration.
Revenue increased 11% on a reported basis and 1
Via MarketBeat · October 27, 2026
Repligen (NASDAQ:RGEN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 10.9% yea...
Via StockStory · October 27, 2026
Repligen Corp (NASDAQ:RGEN) Combines Strong Growth with a Constructive Technical Setupchartmill.com
Via Chartmill · September 5, 2026
Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setupchartmill.com
Via Chartmill · July 30, 2026
Repligen (NASDAQ:RGEN) Rallies as Quality Stock Delivers Earnings Beatchartmill.com
Via Chartmill · July 28, 2026
Repligen (RGEN) Q3 earnings report preview: what to look for
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before market hours. Here’s what to expect. Replig...
Via StockStory · October 25, 2026
Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...
Via StockStory · October 16, 2026
Why Freshworks Stock Bumped Higher Todayfool.com
It's about to join a famous small-cap stock index.
Via The Motley Fool · October 6, 2026
3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...
Via StockStory · October 2, 2026
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7%...
Via StockStory · September 9, 2026
1 Profitable Stock on Our Buy List and 2 We Brush Off
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via StockStory · August 28, 2026
3 High-Flying Stocks with Warning Signs
“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Via StockStory · August 24, 2026
3 Hyped Up Stocks We Keep Off Our Radar
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Via StockStory · August 21, 2026
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Via StockStory · August 16, 2026
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...
Via StockStory · August 13, 2026
Why Repligen (RGEN) Stock Is Up Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 14.6% in the afternoon session after the company reported ...
Via StockStory · July 28, 2026
Repligen Q2 Earnings Call Highlightsmarketbeat.com
Repligen (NASDAQ:RGEN) reported second-quarter 2026 revenue of $204 million, up 12% year over year on a reported basis and 13% organically, as demand for proteins, analytics products and recurring consumables supported growth. The company also raised its full-year organic revenue growth and adjusted
Via MarketBeat · July 28, 2026
Which stocks are gapping on Tuesday?chartmill.com
Via Chartmill · July 28, 2026
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 11.9% ...
Via StockStory · July 28, 2026
Repligen (RGEN) Q2 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday morning. Here’s what you need to know. Repligen bea...
Via StockStory · July 26, 2026
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC...
Via StockStory · July 24, 2026
3 Cash-Producing Stocks That Concern Us
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Via StockStory · July 24, 2026
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reachmarketbeat.com
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing.
Presi
Via MarketBeat · July 22, 2026
Why Repligen (RGEN) Stock Is Trading Lower Today
What Happened? Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 7% in the morning session after investors reacted to the com...
Via StockStory · July 21, 2026